TOTAL IMMUNOGLOBULIN E REDUCTION WITH DUPILUMAB IN PEDIATRIC MODERATE-TO-SEVERE ATOPIC DERMATITIS: 1.5-YEAR FOLLOW-UP DATA
Excellence in Pediatrics Abstracts · 2025 · 17
DOI: 10.66584/eip2025-244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Excellence in Pediatrics Abstracts, 2025. Verfasst von Amy Paller und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In children, Immunoglobulin E (IgE) sensitization may play a role in the sequential development of atopic diseases, also known as the atopic march. Previous reports show that dupilumab treatment decreases IgE levels in pediatric and adult patients with moderate-to-severe atopic dermatitis (AD) over 16 and 52 weeks, respectively. This analysis evaluated changes in serum total IgE levels, a biomarker associated with disease burden and atopic comorbidities, during 1.5 years of dupilumab treatment in children aged 6 to 11 years with moderate-to-severe AD.
Methods
In LIBERTY PED OLE (NCT02612454), an ongoing open-label extension (OLE), patients aged 6 to 11 years with moderate-to-severe AD received weight-tiered dupilumab based on baseline weight (200 mg every 2 weeks (q2w): 30 kg to
Zitieren
APA
Paller, A., Siegfried, E., Beck, L., Eichenfield, L., Boguniewicz, M., Morita, H., Ma, Y., Cyr, S., & Prescilla, R. (2025). TOTAL IMMUNOGLOBULIN E REDUCTION WITH DUPILUMAB IN PEDIATRIC MODERATE-TO-SEVERE ATOPIC DERMATITIS: 1.5-YEAR FOLLOW-UP DATA. Excellence in Pediatrics Abstracts, 17. https://doi.org/10.66584/eip2025-244
Vancouver
Paller A, Siegfried E, Beck L, Eichenfield L, Boguniewicz M, Morita H, et al. TOTAL IMMUNOGLOBULIN E REDUCTION WITH DUPILUMAB IN PEDIATRIC MODERATE-TO-SEVERE ATOPIC DERMATITIS: 1.5-YEAR FOLLOW-UP DATA. Excellence in Pediatrics Abstracts. 2025;17. doi:10.66584/eip2025-244
BibTeX
@article{Paller2025,
author = {Paller, Amy and Siegfried, Elaine and Beck, Lisa and Eichenfield, Lawrence and Boguniewicz, Mark and Morita, Hideaki and Ma, Yonghao and Cyr, Sonya and Prescilla, Randy},
title = {TOTAL IMMUNOGLOBULIN E REDUCTION WITH DUPILUMAB IN PEDIATRIC MODERATE-TO-SEVERE ATOPIC DERMATITIS: 1.5-YEAR FOLLOW-UP DATA},
journal = {Excellence in Pediatrics Abstracts},
year = {2025},
volume = {17},
doi = {10.66584/eip2025-244}
}
EUVIMED